Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 3, Pages 980-989Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI64099
Keywords
-
Categories
Funding
- National Institute on Aging
- New Scholar Award from the Ellison Medical Foundation
- NIH
- American Federation for Aging Research
- Starr Foundation
- Koch Institute Frontier Research Program
- Ellison Medical Foundation
Ask authors/readers for more resources
Rapamycin, an inhibitor of mechanistic target of rapamycin (mTOR), has the strongest experimental support to date as a potential anti-aging therapeutic in mammals. Unlike many other compounds that have been claimed to influence longevity, rapamycin has been repeatedly tested in long-lived, genetically heterogeneous mice, in which it extends both mean and maximum life spans. However, the mechanism that accounts for these effects is far from clear, and a growing list of side effects make it doubtful that rapamycin would ultimately be beneficial in humans. This Review discusses the prospects for developing newer, safer anti-aging therapies based on analogs of rapamycin (termed rapalogs) or other approaches targeting mTOR signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available